ADC Therapeutics.

Moving science forward.

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Dedicated to improving outcomes

ADC Therapeutics has a deep understanding of antibody drug conjugate technology and the oncology treatment landscape. The company is dedicated to efficiently progressing its potential best-in-class PBD-armed ADCs to address significant unmet medical needs and improve outcomes for those with difficult-to-treat cancers.

Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London (R&D), New Jersey (Clinical and Commercial) and the San Francisco Bay Area (CMC).

“Providing unique, targeted therapies for those
in need isn’t just a priority, it’s a privilege.”

— Chris Martin, CEO and Co-Founder, ADC Therapeutics

Corporate Video

Our History

June 2011 — ADC Therapeutics founded as a spinoff from Spirogen Ltd, which was founded in 2000 and was an early innovator in PBD-based ADC research

June 2013 — Genmab and ADC Therapeutics enter co-development collaboration for camidanlumab tesirine (Cami)

October 2013 — AstraZeneca’s MedImmune acquires Spirogen Ltd and makes investment in ADC Therapeutics

June 2015 — Dr. Chris Martin appointed CEO

February 2016 — 1st patient enrolled in phase 1 clinical trial of camidanlumab tesirine (Cami) in acute myeloid leukemia

March 2016 — 1st patient enrolled in phase 1 clinical trial of loncastuximab tesirine (Lonca) in CD-19 positive B-cell non-Hodgkin lymphoma

June 2017 — 1st clinical data presented on the ADC drug candidates loncastuximab tesirine (Lonca) and camidanlumab tesirine (Cami)

October 2019 — 1st patient enrolled in phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory Hodgkin lymphoma

January 2020 — Announced positive results from pivotal phase 2 clinical trial of loncastuximab tesirine (Lonca) in relapsed or refractory DLBCL

March 2020 — Ron Squarer, former CEO of Array BioPharma, Inc appointed Chairman of the Board

May 2020 — $267 million IPO with the NYSE ticker “ADCT”

Our Purpose

Our Mission

We are confronting cancer with the full potential of our science, bringing unique, targeted therapies and hope to patients and their families.

Our Vision

We will transform what patients and their families can expect from cancer therapy.

Our Values

PATIENTS: Patients and their families are at the core of everything we do; they inspire our scientific creativity and innovation

CHARACTER: We are open, honest, trustworthy, and respectful in our words and actions

URGENCY: We operate with a sense of urgency in all that we do

PEOPLE: We encourage individuals to continually learn and grow so that everyone can work at their full potential

Our Leadership
and the Board of Directors

Partnering

At ADC Therapeutics, we are on a mission to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families. To help support this mission, we actively seek innovative collaborations and strategic business development opportunities.

To start the conversation about partnering with ADC Therapeutics, please contact us at partnering@adctherapeutics.com.